A/Prof Jeremy Shapiro named inaugural winner of the Doug Lording Research Award

Date: 09/03/2021

In 2020 Cabrini Research established the Doug Lording Research Award. Named in honour of the founder of the Cabrini Institute, Associate Professor Doug Lording AM, the award is presented to Cabrini individuals for outstanding achievements in clinical, applied or basic research. The inaugural winner for 2020 was Cabrini medical oncologist and researcher, Associate Professor Jeremy Shapiro.

A/Prof Shapiro specialises in cancers of the gastrointestinal (bowel, oesophagus, stomach, pancreas) and genitourinary systems (prostate, bladder, kidney, and testicular). As an associate professor in the Department of Medicine, Monash University, he is also involved in teaching and clinical research, with a particular focus on new treatment options for colon and prostate cancer.

A/Prof Shapiro

A/Prof Shapiro

A/Prof Shapiro started his research career by completing a three year oncology fellowship at the National Cancer Institute, USA. He returned to Australia in 1998, and has worked as a medical oncologist at Cabrini Health (and the Alfred Hospital) ever since. He has remained active in clinical research, which he believes is fundamental to improving outcomes for cancer patients. He has authored more than 100 publications and has delivered more than 250 abstracts and presentations. A/Prof Shapiro was also a key player in the development of a national coordinated clinical research program for gastro-intestinal cancer, the Australasian Gastro-Intestinal Trials Group (AGITG), and was a principal investigator on the international research team that developed Cetuximab, as the first molecular targeted therapy in advanced colorectal cancer. He has evaluated many novel therapies through clinical trials, allowing early access to these therapies for Cabrini patients. He has also been a leading advisor and contributor to Australian clinical databases for more than 15 years. He is a strong advocate for patients having access to clinical trials, and has been the lead researcher on hundreds of oncology clinical trials during his career.

A/Prof Shapiro has made significant contributions throughout his career in leadership, mentorship and contribution to research discoveries at Cabrini. These contributions have made a lasting impact on the gastrointestinal and genitourinary research fields and guided the development of new research directions. When asked about his vision for future research at Cabrini, A/Prof Shapiro said “to improve the outcomes for cancer patients, by involving as many as possible in direct clinical trial research or through database participation”.

“We know that clinical trial participation improves outcomes, yet less than five per cent of cancer patients in Australia currently participate in trials. At the USA National Cancer Institute it is 100 per cent. We need to greatly increase our trial participation rates, which we are striving to do at Cabrini. Big data will also be key in moving forward, where multiple hospitals all contribute data to build large complex patient datasets. This will allow us to broaden our research scope, look at our own data from a quality control perspective and benchmark ourselves against other hospitals.”